Status:
UNKNOWN
Single Dose of Clonazepam Versus Intermiittent Diazepam for Febrile Seizures Prevention
Lead Sponsor:
Queen Sirikit National Institute of Child Health
Conditions:
Recurrent Febrile Convulsion
Eligibility:
All Genders
6-60 years
Phase:
NA
Brief Summary
To study the efficacy and safety of single dose clonazepam compared with intermittent oral diazepam for prevention of recurrent febrile seizures in children who had three or more febrile seizures.
Detailed Description
Febrile seizures are the most common type of seizures disorder of young children. The risk of recurrences are 33 percent overall, half of them had at least one recurrent seizure (the 3rd febrile seizu...
Eligibility Criteria
Inclusion
- age 6-60 months at date of enrollment
- 3 or more episodes of clinically diagnosed febrile seizures
Exclusion
- history of afebrile seizures or any history suggested the epilepsy
- history of previous brain insults; CNS infection, birth trauma, traumatic brain injury.
- delayed developmental milestones
- abnormal neurological examinations
- currently treatment by continous antiepileptic drug(s)
- A contraindication to Clonazepam, Diazepam such as drug hypersensitivity, liver disease.
- Predictable lack of available of follow up.
Key Trial Info
Start Date :
May 13 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2023
Estimated Enrollment :
74 Patients enrolled
Trial Details
Trial ID
NCT04364321
Start Date
May 13 2020
End Date
June 1 2023
Last Update
August 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Sirikit National Institute of Child Health
Ratchathewi, Bangkok, Thailand, 10400